John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK.
J Parkinsons Dis. 2024;14(7):1283-1300. doi: 10.3233/JPD-240353.
Inflammation and immune dysregulation have been linked to the pathogenesis and progression of Parkinson's disease (PD), and represent an attractive target for therapeutic intervention, given the potential for repurposing of existing anti-inflammatory and immunomodulatory agents. Despite the fact that initial studies of drugs with secondary anti-inflammatory effects did not yield positive results, agents specifically targeting immune and inflammatory pathways may hold more promise. This article will briefly review the evidence base for targeting the immune system and neuroinflammation in PD, and discuss in detail the recently completed and currently active trials of primary anti-inflammatory/immunomodulatory drugs in PD.
炎症和免疫失调与帕金森病 (PD) 的发病机制和进展有关，鉴于现有抗炎和免疫调节药物的潜在用途，它们是治疗干预的一个有吸引力的目标。尽管最初研究具有次要抗炎作用的药物并未产生阳性结果，但专门针对免疫和炎症途径的药物可能更有希望。本文将简要回顾靶向治疗 PD 中免疫系统和神经炎症的证据基础，并详细讨论最近完成和目前正在进行的原发性抗炎/免疫调节药物治疗 PD 的临床试验。
